Here’s what you should know:
1. Takeda transferred a portion of its research business to the newly formed company.
2. Axcelead will combine Takeda’s drug discovery knowledge with its research facilities “to offer high-value drug discovery services.”
3. Axcelead will support Takeda’s group business efforts, but will also support other pharmaceutical companies, biotechnology ventures and research institutions.
More articles on improving performance:
2-level spinal fusions safe in outpatient settings, new study finds: 5 things to know
Xenco Medical launches spine system for ASCs nationally: 5 things to know
Influencing the bottom line — Dr. Allston Stubbs on diversified caseloads, growth and major specialties
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
